Melhem Solh

ABCL-853: Vispa-Cel, an Allogeneic Anti-CD19 CAR-T Therapy With a PD-1 Knockout, in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ANTLER Phase 1 Clinical Trial)

Mohamad Cherry, Houston Holmes, James Essell, Ayad Hamdan et autres

us, au, il (code pays fourni par la source)

POSTER: ABCL-853: Vispa-Cel, an Allogeneic Anti-CD19 CAR-T Therapy With a PD-1 Knockout, in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ANTLER Phase 1 Clinical Trial)

Mohamad Cherry, Houston Holmes, James Essell, Ayad Hamdan et autres

us, au, il (code pays fourni par la source)

Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML

Mark J. Levis, Mehdi Hamadani, Brent R Logan, Richard J. Jones et autres

BMT CTN 1506 ("MORPHO") was a phase 3 study of post-hematopoietic cell transplantation (HCT) maintenance with gilteritinib versus placebo for patients with FLT3-ITD-mutated acute myeloid leukemia (AML) in first remission. Subgroup analysis indicated a significant benefit of post-HCT gilteritinib for participants in …

us, kr, de, jp, gb (code pays fourni par la source)

Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL

Tamer Othman, Gregory W. Roloff, Katharine Miller, Amy Zhang et autres

ABSTRACT: Brexucabtagene autoleucel (brexu-cel) produces high rates of measurable residual disease-negative (MRD-) complete response (CR) in adult patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL); however, subsequent relapses remain frequent. It is unclear whether maintenance with tyrosine kinase inhibitors (TKIs) can …

us (code pays fourni par la source)

Real-world toxicity of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

Noam E. Kopmar, Ted Gooley, Gregory W. Roloff, Amy Zhang et autres

ABSTRACT Brexucabtagene autoleucel (brexu-cel) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy directed to CD19 that is approved for use in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Pivotal trial data and real-world experience (RWE) studies show high response …

Genomics of Acute Myeloid Leukemia at Diagnosis and Remission

Kai Yu, Laura W. Dillon, Jesse M. Tettero, Gege Gui et autres

Abstract Accurate and comprehensive genetic characterization of acute myeloid leukemia (AML) is essential for diagnosis, prognostication, and treatment selection. We report here, in 255 adults with AML enrolled in a prospective clinical protocol at 18 major cancer centers across the USA, the …

ca, us, Afrique du Sud, nl (code pays fourni par la source)

Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1

Krina Patel, Binod Dhakal, Gurbakhash Kaur, Richard T. Maziarz et autres

Abstract Background: Anitocabtagene autoleucel (anito-cel) is an autologous anti–BCMA chimeric antigen receptor (CAR) T-cell therapy with a novel D-domain binder under development for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM). D-Domain attributes, including small size, simple structure, and fast off-rate, …

us, au, gb (code pays fourni par la source)

Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib

Mark J. Levis, Mehdi Hamadani, Brent R. Logan, Richard J. Jones et autres

Abstract Aims BMT CTN 1506 (“MORPHO”) was a global phase 3 study of post-hematopoietic cell transplantation (HCT) maintenance with gilteritinib versus placebo for patients with FLT3-ITD-mutated AML in CR1. The study did not meet its primary endpoint of improved relapse-free survival (RFS) …

us, ch, Afrique du Sud, es, kr, de, jp, gb (code pays fourni par la source)

Pre-emptive multidisciplinary approach to overcome the negative impact of high psychosocial risk factor on outcomes after allogeneic hematopoietic cell transplantation

Dawn Speckhart, Krishi Patel, Jennifer Guevara, Joyce Izundu et autres

Abstract Psychosocial factors in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) have long been recognized as important health determinants contributing to disparities in survival and transplant outcomes. Studies looking at the relationship between socioeconomic status (SES), race, and ethnicity have shown …

us (code pays fourni par la source)

Melphalan versus cyclophosphamide combined with fludarabine and low dose total body irradiation (TBI) prior to ptcy-based allogeneic transplantation

Scott R. Solomon, Lizamarie Bachier‐Rodriguez, Joseph Maakaron, Katelin C Jackson et autres

Abstract A preparative regimen of fludarabine, cyclophosphamide (Cy) and low dose TBI 200cGy (FC-TBI) followed by post-transplant Cy (PTCy) is one of the most widely utilized conditioning platforms for nonmyeloablative peripheral blood stem cell transplantation (PBSCT). It provides reliable engraftment in patients …

us (code pays fourni par la source)

Age-related left-digit bias in selection of patients referred for autologous and allogeneic hematopoietic transplantation: An analysis of 877 patients referred to a single center

Asad Bashey, Xu Zhang, H. Kent Holland, Lizamarie Bachier‐Rodriguez et autres

Abstract Left-Digit Bias (LDB) is a well described cognitive phenomenon that results in greater emphasis of the left-most digit of a continuous variable when making decisions (Sokolova et al, J Marketing Research 2020 v 57: p771). Age-related left-digit bias (ARLDB) can result …

us (code pays fourni par la source)

Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 1506

Sameem Abedin, Victor Baidoo, Aniko Szabo, Richard J. Jones et autres

Abstract INTRODUCTION Allogeneic hematopoietic cell transplantation (alloHCT) is indicated in patients (pts) with FLT3-ITD mutated AML. The randomized BMT CTN 1506 trial (Levis et al. JCO) demonstrated that maintenance with FLT3 inhibitor gilteritinib (gilt) significantly improved relapse-free survival (RFS) among pts with …

us, ch, es, kr, de, jp (code pays fourni par la source)